Table 3—

Before and after 12 weeks of nasal continuous positive airway pressure treatment in 29 subjects

	Baseline	After 12 weeks	p-value^#
AHI events·h⁻¹	36.8 (19.0–59.3)	0.6 (0–1.1)	<0.001
ESS	10 (7–15)	9 (5–14)	0.253
Waist circumference cm	94 (89–100)	95 (88.3–100.0)	0.966
BMI kg·m⁻²	26.7 (25.0–30.3)	26.8 (25.4–29.8)	0.421
MRI visceral fat cm³	1113.9 (730.1–1431.3)	1002.4 (870.2–1270.7)	0.407
MRI subcutaneous fat cm³	2211.4 (1510.5–2945.6)	2102.9 (1465.1–2731.9)	0.527
K_itt %·min⁻¹	6.6 (5.2–8.7)	6.3 (4.3–9.1)	0.690
HOMA	2.5 (1.5–3.4)	2.1 (1.5–3.4)	0.511
Serum insulin mIU·L⁻¹	10.9 (7.3–14.0)	10.7 (7.1–15.4)	0.199
Plasma glucose mmol·L⁻¹	4.9 (4.7–5.4)	5.1 (4.7–5.3)	0.954
Systolic BP mmHg	132 (122–141)	123 (117–134)	0.021
Diastolic BP mmHg	81 (73–88)	76 (71–82)	0.042
Total cholesterol mmol·L⁻¹	5.1 (4.8–5.7)	4.8 (4.2–5.6)	0.016
Triglycerides mmol·L⁻¹	1.8 (1.4–2.3)	1.5 (1.2–2.1)	0.028
HDL cholesterol mmol·L⁻¹	1.1 (0.9–1.3)	1.1 (1.0–1.3)	0.974
LDL cholesterol mmol·L⁻¹	3.2 (2.8–3.6)	3.1 (2.5–3.7)	0.189
Apolipoprotein B mmol·L⁻¹	1.1 (0.9–1.2)	1.0 (0.8–1.1)	0.003
Urinary norepinephrine nmol·mmol⁻¹ creatinine	19.0 (15.3–22.0) (n = 22)	15.5 (11.0–17.8)	0.022
Urinary normetanephrine nmol·mmol⁻¹ creatinine	12.0 (9.4–15.0) (n = 27)	11 (7.5–13.0)	0.063
Urinary epinephrine nmol·mmol⁻¹ creatinine	4.1 (3.4–6.1) (n = 22)	3.6 (1.95.2)	0.027
Urinary metanephrine nmol·mmol⁻¹ creatinine	9.5 (7.0–12.0) (n = 26)	9.3 (6.8–12.3)	0.399

Data are presented as median (interquartile range), unless otherwise stated. (n = ) refers to patients with specimens at both baseline and 12-week reassessment AHI: apnoea/hypopnoea index; ESS: Epworth sleepiness score; BMI: body mass index; MRI: magnetic resonance imaging; K_itt: glucose disappearance rate for estimating insulin sensitivity; HOMA: homeostasis model assessment for estimating insulin resistance; BP: blood pressure; HDL: high-density lipoprotein; LDL: low-density lipoprotein. ^#: within group comparisons by Wilcoxon signed rank tests.